NSAIDs Marketed In US Will Have Stronger Label Warning About Risks During Late Pregnancy
In Drug Safety Communication, FDA says it is requiring labeling changes for Rx as well as OTC NSAIDs due to risk of rare but serious kidney problems in an unborn baby.
You may also be interested in...
FTDA and FTC warn Patriot Supreme about noncompliant claims on its website and social media pages promoting CBD to prevent or treat infections from the coronavirus. However, a release Patriot Supreme distributed in July promoting CBD as a COVID-19 remedy remains in online circulation.
“To the extent these claims pertain to the ingestion of peanuts, they are not consistent with the claim in the  Letter of Enforcement Discretion FDA issued in response to a petition for a qualified health claim for ground peanuts and reduced risk of developing peanut allergy,” state CFSAN officials.
Warnings state each’s firm products “are concerning from a public health perspective because they are labeled to contain the ingredients bloodroot (Sanguinaria canadensis) and zinc chloride … known corrosive agents.” The combination results in a corrosive topical agent capable of indiscriminately damaging healthy and diseased tissue alike.